MK 5160

Drug Profile

MK 5160

Alternative Names: MK5160

Latest Information Update: 10 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antihyperglycaemics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 12 Apr 2017 Phase-I clinical trials in Type-1 diabetes mellitus in USA (SC) (NCT03095651)
  • 12 Apr 2017 Phase-I clinical trials in Type-2 diabetes mellitus in USA (SC) (NCT03095651)
  • 06 Apr 2017 Merck Sharp & Dohme plans the MK-5160-002 phase I trial for Type-1 diabetes mellitus and Type-2 diabetes mellitus in USA (NCT03095651)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top